Immediate post-doxorubicin drug-eluting beads chemoembolization Mr Apparent diffusion coefficient quantification predicts response in unresectable hepatocellular carcinoma

A pilot study

Nima Kokabi, Juan C. Camacho, Minzhi Xing, Faramarz Edalat, Pardeep Kumar Mittal, Hyun S. Kim

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Purpose To investigate magnetic resonance imaging (MRI) diffusion-weighted imaging (DWI) of hepatocellular carcinoma (HCC) immediately post-doxorubicin drug-eluting beads transcatheter arterial chemoembolization (DEB-TACE) therapy as an early imaging biomarker of therapy response. Materials and Methods In a single-center prospective correlative study, 12 consecutive patients, median age 64 years, underwent DEB-TACE and dynamic contrast-enhanced (DCE) and DWI (b = 50,400,800 s/mm2) MRI at baseline with respect to first DEB-TACE, within 3 hours, and at 1 and 3 months posttherapy. DCE imaging response was evaluated according to target mRECIST and EASL. Relative change (RC) in apparent diffusion coefficient (ADC) of treated lesions was measured on follow-ups. Correlation between ADC RC in tumors and anatomical response were evaluated with paired t-test and receiver operator characteristic (ROC) curve. Survival from first DEB-TACE was estimated using Kaplan-Meier and log-rank analysis. Results Compared to baseline, mean ADC increased significantly for responders within 3 hours post-DEB-TACE (0.73 ± 0.20 mm2/s vs. 0.99 ± 0.28 mm2/s × 10-3 (P = 0.001)). There was no significant change in ADC within 3 hours for nonresponders. ADC RC threshold of 20% immediately post-DEB-TACE showed 100% sensitivity and specificity in predicting anatomical response at 1 and 3 months with patients with ≥20% ADC increase demonstrated significantly prolonged mean overall survival compared to others (25.4 vs. 13.3 months (P = 0.017)). Conclusion ADC relative change of ≥20% immediately post-DEB-TACE is an accurate predictor of objective and quantitative treatment response and prolonged survival in unresectable HCC. J. Magn. Reson. Imaging 2015;42:981-989.

Original languageEnglish (US)
Pages (from-to)981-989
Number of pages9
JournalJournal of Magnetic Resonance Imaging
Volume42
Issue number4
DOIs
StatePublished - Oct 1 2015
Externally publishedYes

Fingerprint

Doxorubicin
Hepatocellular Carcinoma
Pharmaceutical Preparations
Survival
Diffusion Magnetic Resonance Imaging
Therapeutics
Biomarkers
Magnetic Resonance Imaging
Prospective Studies
Sensitivity and Specificity
Neoplasms

Keywords

  • ADC
  • DEB-TACE
  • HCC
  • imaging biomarker
  • immediate
  • response
  • survival

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Immediate post-doxorubicin drug-eluting beads chemoembolization Mr Apparent diffusion coefficient quantification predicts response in unresectable hepatocellular carcinoma : A pilot study. / Kokabi, Nima; Camacho, Juan C.; Xing, Minzhi; Edalat, Faramarz; Mittal, Pardeep Kumar; Kim, Hyun S.

In: Journal of Magnetic Resonance Imaging, Vol. 42, No. 4, 01.10.2015, p. 981-989.

Research output: Contribution to journalArticle

@article{c8b7e2bd83c74cd082d72365c583bc34,
title = "Immediate post-doxorubicin drug-eluting beads chemoembolization Mr Apparent diffusion coefficient quantification predicts response in unresectable hepatocellular carcinoma: A pilot study",
abstract = "Purpose To investigate magnetic resonance imaging (MRI) diffusion-weighted imaging (DWI) of hepatocellular carcinoma (HCC) immediately post-doxorubicin drug-eluting beads transcatheter arterial chemoembolization (DEB-TACE) therapy as an early imaging biomarker of therapy response. Materials and Methods In a single-center prospective correlative study, 12 consecutive patients, median age 64 years, underwent DEB-TACE and dynamic contrast-enhanced (DCE) and DWI (b = 50,400,800 s/mm2) MRI at baseline with respect to first DEB-TACE, within 3 hours, and at 1 and 3 months posttherapy. DCE imaging response was evaluated according to target mRECIST and EASL. Relative change (RC) in apparent diffusion coefficient (ADC) of treated lesions was measured on follow-ups. Correlation between ADC RC in tumors and anatomical response were evaluated with paired t-test and receiver operator characteristic (ROC) curve. Survival from first DEB-TACE was estimated using Kaplan-Meier and log-rank analysis. Results Compared to baseline, mean ADC increased significantly for responders within 3 hours post-DEB-TACE (0.73 ± 0.20 mm2/s vs. 0.99 ± 0.28 mm2/s × 10-3 (P = 0.001)). There was no significant change in ADC within 3 hours for nonresponders. ADC RC threshold of 20{\%} immediately post-DEB-TACE showed 100{\%} sensitivity and specificity in predicting anatomical response at 1 and 3 months with patients with ≥20{\%} ADC increase demonstrated significantly prolonged mean overall survival compared to others (25.4 vs. 13.3 months (P = 0.017)). Conclusion ADC relative change of ≥20{\%} immediately post-DEB-TACE is an accurate predictor of objective and quantitative treatment response and prolonged survival in unresectable HCC. J. Magn. Reson. Imaging 2015;42:981-989.",
keywords = "ADC, DEB-TACE, HCC, imaging biomarker, immediate, response, survival",
author = "Nima Kokabi and Camacho, {Juan C.} and Minzhi Xing and Faramarz Edalat and Mittal, {Pardeep Kumar} and Kim, {Hyun S.}",
year = "2015",
month = "10",
day = "1",
doi = "10.1002/jmri.24845",
language = "English (US)",
volume = "42",
pages = "981--989",
journal = "Journal of Magnetic Resonance Imaging",
issn = "1053-1807",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Immediate post-doxorubicin drug-eluting beads chemoembolization Mr Apparent diffusion coefficient quantification predicts response in unresectable hepatocellular carcinoma

T2 - A pilot study

AU - Kokabi, Nima

AU - Camacho, Juan C.

AU - Xing, Minzhi

AU - Edalat, Faramarz

AU - Mittal, Pardeep Kumar

AU - Kim, Hyun S.

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Purpose To investigate magnetic resonance imaging (MRI) diffusion-weighted imaging (DWI) of hepatocellular carcinoma (HCC) immediately post-doxorubicin drug-eluting beads transcatheter arterial chemoembolization (DEB-TACE) therapy as an early imaging biomarker of therapy response. Materials and Methods In a single-center prospective correlative study, 12 consecutive patients, median age 64 years, underwent DEB-TACE and dynamic contrast-enhanced (DCE) and DWI (b = 50,400,800 s/mm2) MRI at baseline with respect to first DEB-TACE, within 3 hours, and at 1 and 3 months posttherapy. DCE imaging response was evaluated according to target mRECIST and EASL. Relative change (RC) in apparent diffusion coefficient (ADC) of treated lesions was measured on follow-ups. Correlation between ADC RC in tumors and anatomical response were evaluated with paired t-test and receiver operator characteristic (ROC) curve. Survival from first DEB-TACE was estimated using Kaplan-Meier and log-rank analysis. Results Compared to baseline, mean ADC increased significantly for responders within 3 hours post-DEB-TACE (0.73 ± 0.20 mm2/s vs. 0.99 ± 0.28 mm2/s × 10-3 (P = 0.001)). There was no significant change in ADC within 3 hours for nonresponders. ADC RC threshold of 20% immediately post-DEB-TACE showed 100% sensitivity and specificity in predicting anatomical response at 1 and 3 months with patients with ≥20% ADC increase demonstrated significantly prolonged mean overall survival compared to others (25.4 vs. 13.3 months (P = 0.017)). Conclusion ADC relative change of ≥20% immediately post-DEB-TACE is an accurate predictor of objective and quantitative treatment response and prolonged survival in unresectable HCC. J. Magn. Reson. Imaging 2015;42:981-989.

AB - Purpose To investigate magnetic resonance imaging (MRI) diffusion-weighted imaging (DWI) of hepatocellular carcinoma (HCC) immediately post-doxorubicin drug-eluting beads transcatheter arterial chemoembolization (DEB-TACE) therapy as an early imaging biomarker of therapy response. Materials and Methods In a single-center prospective correlative study, 12 consecutive patients, median age 64 years, underwent DEB-TACE and dynamic contrast-enhanced (DCE) and DWI (b = 50,400,800 s/mm2) MRI at baseline with respect to first DEB-TACE, within 3 hours, and at 1 and 3 months posttherapy. DCE imaging response was evaluated according to target mRECIST and EASL. Relative change (RC) in apparent diffusion coefficient (ADC) of treated lesions was measured on follow-ups. Correlation between ADC RC in tumors and anatomical response were evaluated with paired t-test and receiver operator characteristic (ROC) curve. Survival from first DEB-TACE was estimated using Kaplan-Meier and log-rank analysis. Results Compared to baseline, mean ADC increased significantly for responders within 3 hours post-DEB-TACE (0.73 ± 0.20 mm2/s vs. 0.99 ± 0.28 mm2/s × 10-3 (P = 0.001)). There was no significant change in ADC within 3 hours for nonresponders. ADC RC threshold of 20% immediately post-DEB-TACE showed 100% sensitivity and specificity in predicting anatomical response at 1 and 3 months with patients with ≥20% ADC increase demonstrated significantly prolonged mean overall survival compared to others (25.4 vs. 13.3 months (P = 0.017)). Conclusion ADC relative change of ≥20% immediately post-DEB-TACE is an accurate predictor of objective and quantitative treatment response and prolonged survival in unresectable HCC. J. Magn. Reson. Imaging 2015;42:981-989.

KW - ADC

KW - DEB-TACE

KW - HCC

KW - imaging biomarker

KW - immediate

KW - response

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=84941993704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941993704&partnerID=8YFLogxK

U2 - 10.1002/jmri.24845

DO - 10.1002/jmri.24845

M3 - Article

VL - 42

SP - 981

EP - 989

JO - Journal of Magnetic Resonance Imaging

JF - Journal of Magnetic Resonance Imaging

SN - 1053-1807

IS - 4

ER -